CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinue production of Fluorognost HIV-1 IFA test kits routinely used for confirmation of HIV-1 antibody-reactive donations. Based on our current testing volume, CTS has sufficient HIV-1 IFA reagent inventory to continue performing this confirmatory test through the end of August 2019.
Check out the Communication page for the complete details on the updated IFA HIV-1 assay or by clicking the link: Communications
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...